[1] Noal S, Joly F, Leblanc E, et al. Management of gestational trophoblastic disease [J].Gynecol Obstet Fertil, 2010, 38(3):193-198.
[2]Seckl MJ, Sebire NJ, Berkowitz RS, et al. Gestational trophoblastic disease [J].Lancet, 2010, 376(9742):717-729.
[3]Oh YJ, Seo YH. A novel chalcone-based molecule, BDP inhibits MDA-MB-231 triplenegative breast cancer cell growth by suppressing Hsp90 function[J]. Oncol Rep, 2017, 38(4):2343-2350.
[4]Belalcazar A, Shaib WL, Farren MR, et al. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells [J]. Cancer, 2017,123(24):4924-4933.
[5]Zhang H, Neely L, Lundgren K, et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance [J]. Int J Cancer, 2010, 126(5):1226-1234.
[6]Soroka J, Wandinger SK, Mausbacher N, et al.Conformational switching of the molecular chaperone Hsp90 via regulated phosphorylation [J].Mol Cell, 2012, 45(4):517-528.
[7]Woyach JA, Shah MH. New therapeutic advances in the management of progressive thyroid cancer [J].Endocr Relat Cancer, 2009, 16(3):715-731.
[8]Jhaveri K, Taldone T, Modi S, et al. Advances in the clinical development of heat shock protein 90(Hsp 90) inhibitors in cancers[J]. Biochim Biophys Acta, 2012, 1823(3):742-755.
[9]Massimini M, Palmieri C, De Maria R, et al.17-AAG and apoptosis, autophagy, and mitophagy in canine osteosarcoma cell lines [J].Vet Patho, 2017, 54(3):405-412.
[10]Weber H, Valbuena JR, Barbhuiya MA, et al.Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer [J].Oncotarget, 2017, 8(16):26169-26184.
[11]Woo JK, Jang JE, Kang JH, et al.Lectin, galactoside-binding soluble 3 binding protein promotes 17-N-allylamino-17-demethoxygeldanamycin resistance through PI3K/Akt pathway in lung cancer cell line [J].Mol Cancer Ther, 2017, 16(7):1355-1365.
[12]Zhang T, Li Y, Zhu Z, et al. MEK inhibition potentiates the activityof Hsp90 inhibitor 17-AAG against pancreatic cancer cells [J]. Mol Pharm, 2010, 7(5):1576-1584.
[13]Wang G, Krishnamurthy K, Tangpisuthipongsa D. Protection of murine neural progenitor cells by the Hsp90 inhibitor17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range [J]. J Neurochem, 2011, 117(4):703-711.
[14]Wang X, Ju W, Renouard J, et al. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor induced lung cancer cell death by blocking the nuclear factor-κB pathway [J]. Cancer Res, 2006, 66(2):1089-1095.
[15]Vlahakis NE, Young BA, Atakilit A,et al. Integrin alpha9beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis [J].J Biol Chem, 2007, 282(20):15187-15196.
[16]Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression [J]. Carcinogenesis, 2007, 28 (4): 858-864.
[17]Hirakawa S, Brown LF, Kodama S, et al.VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites [J]. Blood, 2007, 109 (3):1010-1017.
|